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RESEARCH ARTICLE Open Access
The endogenous soluble VEGF receptor-2 isoform
suppresses lymph node metastasis in a mouse
immunocompetent mammary cancer model
Masa-Aki Shibata1*, Jayakrishna Ambati2, Eiko Shibata1,3, Romulo JC Albuquerque2, Junji Morimoto4, Yuko Ito1,
Yoshinori Otsuki1
Abstract
Background: Cancer metastasis contributes significantly to cancer mortality and is facilitated by
lymphangiogenesis and angiogenesis. A new splicing variant, endogenous soluble vascular endothelial growth
factor receptor-2 (esVEGFR-2) that we recently identified is an endogenous selective inhibitor of
lymphangiogenesis. To evaluate the antimetastatic potential of esVEGFR-2, gene therapy with vector expressing
esVEGFR-2 (pesVEGFR-2) or endostatin (pEndo) as a positive control was conducted on murine metastatic
mammary cancer.
Methods: Syngeneic inoculated metastatic mammary cancers received direct intratumoral injection of pesVEGFR-2,
pEndo or pVec as control, once a week for six weeks. In vivo gene electrotransfer was performed on the tumors
after each injection.
Results: Deaths from metastasis were much lower in the pesVEGFR-2 and pEndo groups than in those of the
pVec. Tumor volume was significantly lower in the pesVEGFR-2 and the pEndo groups throughout the study.
Multiplicity of lymph node and lung metastatic nodules was significantly suppressed in the pesVEGFR-2 and pEndo
groups. Moreover, the total number of overall metastasis including the other organs was also decreased in these
groups. However, pesVEGFR-2 was not able to decrease the number of lungs, ovaries, kidneys and adrenals with
metastasis as counted by unilateral or bilateral metastasis. The number of CD34+/Lyve-1- blood microvessels was
significantly decreased in the pEndo group, while the number of CD34-/Lyve-1+ lymphatic vessels was significantly
decreased in the pesVEGFR-2 and pEndo groups. In addition, a significant reduction in the number of dilated
lymphatic vessels containing intraluminal cancer cells was observed in the pesVEGFR-2 and pEndo groups. Levels
of apoptosis were significantly increased in the pEndo group, whereas the rates of cell proliferation were
significantly decreased in the pesVEGFR-2 and pEndo groups.
Conclusions: Our data demonstrate that esVEGFR-2 can inhibit mainly lymph node metastasis. The antimetastatic
activity of esVEGFR-2 may be of high clinical significance in the treatment of metastatic breast cancer because
lymph node involvement is a most important prognostic factor in cancer patients.
Background
The majority of cancer deaths are due to metastatic
spread of tumor cells. The mortality rate among breast
cancer patients is also largely the result of metastasis,
the common sites being the lymph nodes, lung, liver
and bone. Lymph node metastasis is one of the most
important adverse prognostic factors for breast cancer
[1]. In principle, cancer cells spread through the body
by different mechanisms, such as direct invasion of sur-
rounding tissue, hematogenous metastasis and/or lym-
phatic metastasis. Thus, development of vascular supply
is a key factor in the growth and metastatic spread of
cancers. The ability to block the signaling system that
enables the spread of cancer would be a major step
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forward in the prevention of tumor metastasis, and
would consequently reduce both morbidity and
mortality.
The vascular endothelial growth factor (VEGF)
family of molecules is critical for vascular development
and pathological sprouting. The growth of blood ves-
sels (angiogenesis) is primarily initiated by activation
of VEGFR-1 and VEGFR-2 by VEGF-A, whereas lym-
phangiogenesis is predominantly driven by VEGF-C,
which activates VEGFR-2 and VEGFR-3 expressed in
lymphatic endothelial cells. Recently, blockade of
VEGFR-3 signaling by soluble VEGFR-3 (sVEGFR-3)
or the blocking antibody inhibits lymph node metasta-
sis in experimental animal cancer models and asso-
ciated with reduction in lymphangiogenesis but not
anginogenesis of the tumors [2-6]. More recently, an
endogenous soluble isoform of VEGFR-2 (esVEGFR-2)
that sequesters VEGF-C was identified and shown to
be the first endogenous specific inhibitor of lymphatic
vessel growth [7]. esVEGFR-2 is a truncated form of
230 kDa membrane-bound form of VEGFR-2 resulting
from alternative splicing. In addition, tissue-specific
loss of esVEGFR-2 in mice induces, at birth, sponta-
neous lymphatic invasion of the normally alymphatic
cornea and hyperplasia of skin lymphatics without
affecting angiogenesis. Treatment with esVEGFR-2
inhibits lymphangiogenesis but not angiogenesis
induced by corneal suture injury or transplantation,
enhances corneal allograft survival and suppressed
lymphangioma cell proliferation [7].
VEGF-C is the major lymphangiogenic factor highly
expressed in a variety of malignant tumors including
mammary cancer [8]. Furthermore, over-expression of
VEGF-C has been reported to be associated with a poor
prognosis and lymph node metastasis in breast cancer
patients [9,10]. A number of animal studies using cell
lines [2,11,12] and transgenic mice [13] have been con-
ducted in an attempt to demonstrate that VEGF-C over-
expression is able to promote cancer metastasis. Thus,
tumor cell-derived VEGF-C is thought to enhance
lymph node metastasis. Moreover, VEGF-A is well-
known to exert a crucial role in tumor angiogenesis
[14]. An adequate blood supply is required to sustain
the uncontrolled cell proliferation characteristic of
malignant tumors, and tumorigenesis and metastasis
have been associated with angiogenesis in tumors [14].
Therefore, lymphangiogenesis and angiogenesis in
tumors have become potential targets for cancer ther-
apy. The recent discovery of esVEGFR-2 [7] and its
selective inhibition of VEGF-C signaling, led to the
interrogation of whether it would serve as a therapeutic
tool for preventing cancer metastasis and dissecting the
precise individual contribution of lymphangiogenesis
and VEGF-C signaling in this milieu.
In the present study, we examined whether gene ther-
apy with an alternative splicing variant esVEGFR-2 (an
endogenous inhibitor of lympphangiogenesis) might lead
to suppression of lymphatic metastasis in a mouse
immunocompetent mammary cancer model. In addition,
since endostatin is also a naturally occurring molecule
and exerts both inhibitions of blood and lymphatic ves-
sels, this protein served as a positive control [15,16].
Methods
Vectors
The open reading frame of esVegfr2 was cloned from
mouse corneal cDNA and inserted into a pcDNA3.1 vec-
tor for in vivo overexpression as previously described [7].
Empty vector pcDNA3.1 was used as a control vector
and referred to as pVec. The plasmid pBLAST-mEndo
XVIII (InvivoGen, Inc. San Diego, CA, USA), which
encodes murine endostatin with the addition of the IL-2
signal sequence for secretion, was used as a positive con-
trol [15]. For simplicity in this manuscript, the vectors
are referred to as pesVEGFR-2 and pEndo, respectively.
All plasmid vectors were extracted from Escherichia coli
(DH5a strain) and purified by means of a modified alka-
line lysis procedure using a Plasmid Maxi Kit (Qiagen
Inc., Valencia, CA, USA) and further purified with centri-
fugal filters (Ultrafree-MC, Millipore Co., Bedford, MA,
USA).
Cell line and animals
Mouse mammary tumor virus (MMTV), purified from
medium in which Jyg-MC cells (established from mam-
mary tumors of the Chinese wild mouse) were grown,
was inoculated into the inguinal mammary glands of
female BALB/c mice, resulting in the development of
mammary carcinomas [17]. The BJMC3879 mammary
adenocarcinoma cell line was subsequently derived from
a metastatic focus within a lymph node from one of the
inoculated BALB/c mice and the cell line continues to
show a high metastatic propensity, especially to lymph
nodes and lungs, a trait retained through culture [18-20].
This cell line and inoculated tumors expressed VEGF-C
and VEGFR-3 [21]. The BJMC3879luc2 mammary carci-
noma cell line was generated by stable transfection with
luc2 gene (an improved firefly luciferase gene) to parent
cell line BJMC3879 cells [22]. BJMC3879luc2 cells were
maintained in RPMI 1640 medium containing 10% fetal
bovine serum with streptomycin/penicillin in an incuba-
tor under 5% CO2 at 37°C.
A total of 30 female, six-week-old BALB/c mice was
used in this study (Japan SLC, Hamamatsu, Japan). The
animals were housed five per plastic cage on wood chip
bedding with free access to water and food under con-
trolled temperature (21 ± 2°C), humidity (50 ± 10%),
and lighting (12:12 hour light:dark cycle). All animals
Shibata et al. BMC Medicine 2010, 8:69
http://www.biomedcentral.com/1741-7015/8/69
Page 2 of 13
were held for a one-week acclimatization period before
study commencement. All manipulations of mice were
performed in accordance with the procedures outlined
in the Guide for the Care and Use of Laboratory Ani-
mals in Osaka Medical College, Japanese Government
Animal Protection and Management Law (No.105) and
Japanese Government Notification on Feeding and Safe-
keeping of Animals (No.6).
In vivo esVEGFR-2 gene therapy on mammary cancer
model
BJMC3879luc2 cells (2.5 × 106 cells/0.3 ml in phos-
phate buffered saline) were inoculated into the right
inguinal region of 30 female BALB/c mice. The ani-
mals were then randomly allocated into three groups
of 10 mice each: the pVec (control), pesVEGFR-2, or
pEndo groups. Two weeks post-inoculation, when the
tumors had reached 0.4 to 0.5 cm in diameter, we
injected pVec, pesVEGFR-2 or pEndo directly into the
tumors and then immediately performed in vivo gene
electrotransfer by applying a conductive gel (Echo Jelly;
Aloka Co., Ltd., Tokyo, Japan) topically to the
unshaved skin over the injected tumor. The vectors
were injected using a 27-gauge needle at a concentra-
tion of 0.5 μg/μl in sterile saline while the animals
were under isoflurane anesthesia. A total volume of
150 μl was introduced into larger tumors, while smal-
ler tumors of 0.6 to 0.7 cm were infused until we
detected leakage of the vector solution. Electric pulses
were delivered directly to the tumor via “forceps” plati-
num plate electrodes (CUY650-10; Nepa Gene Co.
Ltd., Ichikawa, Japan) using a CUY21EDIT square-
wave electropulser (Nepa Gene Co., Ltd.). Conditions
for gene electrotransfer used in the present study were
intratumoral injection of 50 to 75 μg plasmid (depen-
dent on tumor size as mentioned above), eight pulses
with a pulse length of 20 milliseconds at 100 volts.
The parameters for optimal gene electrotransfer were
previously determined [15,18,20].
Using calipers, we measured the size of each treated
mammary tumor weekly and calculated tumor volumes
using the formula maximum diameter × (minimum dia-
meter)2 × 0.4 [23]. Individual body weights were also
recorded at weekly intervals. All surviving animals were
injected intraperitoneally with 50 mg/kg 5-bromo-2’-
deoxyuridine (BrdU; Sigma Co., St. Louis, MO, USA) at
one hour prior to sacrifice. After six weeks of treatment,
all mice were euthanized under isoflurane anesthesia
and the mammary tumors and certain lymph nodes
(that is, nodes from axillary and femoral regions as well
as any that appeared abnormal) were removed. We then
immediately fixed a portion of each tissue sample in
10% phosphate-buffered formalin and processed through
to paraffin embedding; an additional portion of each
tumor was also immediately frozen in liquid nitrogen
for molecular analysis. Lungs were routinely inflated
with the fixative, excised and immersed back into the
fixative. We subsequently trimmed and examined all
lobes for metastatic foci before processing through his-
tology, where they were cut into 4-μm-thick sections
and stained with hematoxylin and eosin (H&E) for his-
topathological examination or remained unstained sec-
tions for immunohistochemistry.
Bioluminescence imaging in vivo
At Week 6, while under isoflurane inhalation using an
SBH Scientific anesthesia system (SBH Designs Inc.,
Windsor, Ontario, Canada), a minimum of five mice
from each group were injected intraperitoneally with D-
luciferin potassium salts (Wako Pure Chemical Indus-
tries, Osaka, Japan) at 3 mg/mouse. Bioluminescence
imaging with a Photon Imager (Biospace Lab, Paris,
France) was performed. The bioluminescent signals
received during the six-minute acquisition time were
imaged and quantified using Photovision software (Bio-
space Lab).
p53 immunohistochemistry
The labeled streptavidin-biotin (LSAB) method (Dako
Co., Glostrup, Denmark) was used for p53 immunohis-
tochemistry. Unstained sections were immersed in dis-
tilled water and heated for antigen retrieval prior to
incubation with a p53 mouse monoclonal antibody
(Clone Pab240; Santa Cruz Biotechnology, Santa Cruz,
CA, USA) that reacts to the mutant protein in fixed
specimens.
Blood and lymphatic microvascular densities in mammary
tumors
Immunohistochemistry was performed on samples using
the blood and lymphatic vessel markers CD34 and Lyve-
1 respectively to quantitatively assess the number of
microvessels present in primary mammary carcinomas.
Rat anti-CD34 (Hycult Biotech, Uden, The Netherlands)
and rabbit anti-LYVE-1 (Acris Antibodies GmbH, Her-
ford, Germany) were used as primary antibodies and
were detected using goat anti-rat Alexa-594 and goat
anti-rabbit Alexa-488 (Molecular Probes, Life Technol.
Corp., Carlsbad, CA, USA). Nuclear staining was per-
formed with Vectashield mounting medium with DAPI
(Vector Labs, Inc., Burlingame, CA, USA). The probes
were then visualized at high magnification (x200) using
a laboratory microscope equipped with a high pressure
mercury burner for fluorescence (Olympus Co., Tokyo,
Japan). The mammary carcinoma tissues immunohisto-
chemically stained were observed and digitally captured
whole periphery of the tumors at high magnification
(x200) under fluorescence with a 590 nm or 495 nm
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excitation filter. The corresponding three images (CD34,
Lyve-1 and DAPI) were merged into a single image and
the number of CD34+/Lyve-1- and the number of
CD34-/Lyve-1+ vessels were counted.
Dilated lymphatic vessels with cancer cell invasion
Mammary tumor sections from paraffin-embedded tis-
sues were immunohistochemically stained using the
LSAB method (Dako Co.). A hamster anti-podoplanin
monoclonal antibody (AngioBio Co., Del Mar, CA,
USA), against a lymphatic endothelium marker was
used. To quantitatively assess the number of lymphatic
vessels having intraluminal tumor cells in whole periph-
ery area of the primary mammary carcinomas, the slides
were scanned at low-power (x100) magnification to
identify podoplanin-positive lymphatic vessels, and were
then confirmed whether the lymphatic vessel contain
mammary cancer cells or not at higher (x200 to 400)
magnification. The number of podoplanin-positive lym-
phatic vessels containing intraluminal tumor cells in
whole periphery of the tumors was counted and
expressed as the average ± SD.
Apoptosis and cell proliferation in mammary tumors
For the quantitative analyses of apoptotic cell death, sec-
tions from paraffin-embedded tumors were assayed
using the terminal deoxynucleotidyl transferase-
mediated dUTP-FITC nick end-labeling (TUNEL)
method in conjunction with an apoptosis in situ detec-
tion kit (Wako Pure Chemical Industries) with minor
modifications to the manufacturer’s protocol. TUNEL-
positive cells (mainly regarded as apoptotic cells) were
counted in viable regions peripheral to areas of necrosis
in tumor sections. The slides were scanned at low-
power (x100) magnification to identify those areas hav-
ing the highest number of TUNEL-positive cells; four
areas neighboring the highest area of TUNEL-positive
cells were then selected and counted at higher (x200 to
400) magnification to obtain mean ± SD values. The
numbers of TUNEL-positive cells were expressed as
numbers per cm2.
The tumors from five animals from each treatment
group were subsequently evaluated for cell proliferation
rates (BrdU labeling indices) as inferred by BrdU incor-
poration. DNA was denatured in situ by incubating
unstained paraffin-embedded tissue sections in 4 N HCl
solution for 20 minutes at 37°C. The incorporated BrdU
was visualized after exposure to an anti-BrdU mouse
monoclonal antibody (Clone Bu20a, Dako Co.). The
numbers of BrdU-positive S-phase cells per 250 mm2
were counted in four random high power (×200) fields
of viable tissue, and the BrdU labeling indices were
expressed as numbers per cm2.
Statistical analyses
Significant differences in the quantitative data between
groups were analyzed using the Student’s t-test via the
Welch method which provides for insufficient homoge-
neity of variance. The differences in metastatic incidence
were examined by Fisher’s exact probability test, with
P < 0.05 or P < 0.01 considered to represent a statisti-
cally significant difference.
Results
Survival rates, body weights and tumor growth in gene
therapy using pesVEGFR-2 or pEndo
Survival rates are shown in Figure 1A. Four animals
(40%) in the pVec (control) group and one animal (10%)
in the pesVEGFR-2 group died at Week 6 due to the
widespread metastasis of mammary carcinoma. Reduc-
tion in body weight of mice was not seen as a result of
any treatment regimen with the exception of the pEnd
group at Week 2 but recovered thereafter (Figure 1B).
The general condition of the animals was good through-
out the experiment. Data for tumor volumes are pre-
sented in Figure 1C. Tumor volume increases were
significantly suppressed in the pesVEGFR-2 and pEndo
groups from Week 2 to the end of the study as com-
pared to the pVec group. Tumor volumes in the pEndo
group (positive control) were significantly smaller than
those in the pesVEGFR-2 group from Week 3 to the
end of the study (Figure 1C).
Mammary carcinoma metastasis
Bioluminescence imaging
Metastasis was visualized by bioluminescence imaging at
Week 6 (Figure 1D-F). The imaging showed a tendency
for decrease of metastatic expansion in mice treated
with pesVEGFR-2 (Figure 1E) and pEndo (Figure 1F) as
compared to control animals (Figure 1D). The magni-
tude of metastasis was measured in each group by biolu-
minescence imaging. As shown in Figure 1G, the levels
were significantly decreased in the pesVEGFR-2 and
pEndo groups as compared to the control group. In
addition, as compared to the pesVEGFR-2 levels, the
levels in the pEndo group were significantly decreased.
Primary implanted mammary carcinoma
Histopathologically, the mammary carcinomas induced
by BJMC3879luc2 cell inoculation proved to be moder-
ately differentiated adenocarcinomas (Figure 2A), which
contain p53 mutation as inferred by immunohistochem-
istry (Figure 2D). The mammary carcinomas showed no
apparent differences between the pVec (Figure 2A) and
pesVEGFR-2 (Figure 2B) groups. However, the mam-
mary carcinoma transfected with pEndo showed spoke-
like cell death regions within viable tumor tissue (Figure
2C). The cell death region was observed along with
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Figure 1 Survival rates, body weights, tumor volumes and bioluminescent imaging in mice receiving esVEGFR-2 gene therapy. Survival
rates (A), body weights (B) and tumor volumes (C) in mammary carcinomas from female BALB/c mice transfected with pVec (control),
pesVEGFR-2 and pEndo vectors using in vivo gene electrotransfer. Each group consisted of 10 mice. A. Survival rates were much lower in the
pVec group than in those of the pesVEGFR-2 and pEndo groups. B. Body weights were similar between pVec group and pesVEGFR-2 or pEndo
groups with exception of the pEndo group at Week 2. C. From Week 1 on, rates of tumor growth (tumor volumes) in the pesVEGFR-2 and
pEndo groups were significantly decreased as compared to the control values, the differences becoming even more pronounced by the
termination of the experiment (Week 6) (**P < 0.01 as compared to the pVec group; †P < 0.01 as compared to the pesVEGFR-2 group). Data
presented are means ± SD values. D-F. Bioluminescent imaging of five mice representative of each group. Bioluminescent imaging showed a
tendency for decreases in extension of metastasis in the pesVEGFR-2 (E) and pEndo (F) groups as compared to the pVec group (D). G.
Quantification of the average bioluminescent signals was significantly decreased in those of the pesVEGFR-2 and pEndo groups (**P < 0.01) as
compared to the control values. As compared to the pesVEGFR-2 group, the levels were further decreased in the pEndo group (†P < 0.01).
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Figure 2 Histopathological findings in mice receiving esVEGFR-2 gene therapy. The implanted mammary carcinomas proved to be
moderately differentiated adenocarcinoma (A-C, scale bar = 50 μm). Histopathologically, no apparent differences in mammary carcinomas were
found between the pVec (A) and pesVEGFR-2 (B) groups. However, mammary carcinomas in the pEndo group showed spoke-like cell death
regions (asterisks) within viable tumor cells (C). The cell death region was observed around blood vessels (asterisk) and apoptotic bodies (arrows)
were seen along with the cell death area (C). p53 immunohistochemistry of mammary carcinoma induced by BJMC3879luc2 cell inoculation
(D, scale bar = 25 μm). Note nuclear staining for abnormal p53 protein, indicating that these cells carry mutant p53. Metastasis to lymph node in
the pVec (E), pesVEGFR-2 (F) and pEndo (G) (E-G, scale bar = 50 μm). Metastatic carcinoma cells were presented in medullary cord and
intraluminal space of the blood vessel (E, arrows). Metastatic carcinoma cells were filled with subcapsular sinus (asterisk) and cortical sinus
(arrow) (F). Fewer lymph nodes with metastasis were found in the therapeutic groups. Metastatic tumor cells were observed in subcapsular sinus
(G, arrow). Metastatic foci in the lung of the pVec, pesVEGFR-2 and pEndo groups (H-J, scale bar = 200 μm). Many metastatic foci and nodules
with small to large were seen in the pVec group (H). Metastatic lung foci were much smaller in the pesVEGFR-2 (I) group than in the control
group (J). No metastatic foci were observed in the lung of mouse given pEndo (J). A-C and E-J, H&E stain; D, p53 immunohistochemistry.
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blood microvessels and apoptotic bodies were also seen
in association with the cell death areas (Figure 2C).
Metastasis to lymph nodes
Representative lymph node metastases are presented in
Figure 2E-G. Many metastatic tumor cells were found in
lymphatic sinus (Figure 2E-G). As shown in Figure 3A,
the number of lymph node metastases per mouse was
significantly lower in the pesVEGFR-2 and the pEndo
groups as compared to the pVec group. Inhibition of
lymph node metastasis in the pEndo group (positive
control) was significantly stronger than in those
observed in the pesVEGFR-2 group (Figure 3A).
Metastasis to lungs
Histopathologically, large metastatic lung nodules
tended to be few in the pesVEGFR-2 group (Figure 2I)
as compared to the pVec group (Figure 2H). In the
pEndo group, no metastatic foci were found (Figure 2J).
Quantitative measurements of the numbers of meta-
static lung nodules > 250 μm per mouse showed a sig-
nificant inhibition of metastasis upon exposure to
pesVEGFR-2 or pEndo (Figure 3B). The number of
metastatic nodules in the pEndo group was significantly
decreased as compared to the pesVEGFR-2 group (Fig-
ure 3B).
Overall metastasis
In metastasis to other organs, metastatic foci were
observed in ovaries, kidneys, adrenals and uterus. With
respect to bilateral organs, one in unilateral metastasis
and two in bilateral metastasis were counted. The multi-
plicity of overall metastasis is presented in Table 1.
Total numbers of organs with metastasis tended to be
much lower in the pesVEGFR-2 and pEndo groups as
compared to the pVec group. The average number of all
organs with metastasis was significantly decreased in the
pesVEGFR-2 and pEndo groups as compared to the
pVec group. In addition, as compared with the pes-
VEGFR-2 group, the pEndo group (positive control)
showed further significant suppression of the average
number of organs with metastasis (Table 1). Further-
more, as shown in the average number of individual
organs with metastasis as counted by unilateral or bilat-
eral metastasis, pesVEGFR-2 did not inhibit metastasis
to lungs, ovaries, kidneys and adrenals (Table 1). In con-
trast, pEndo significantly decreased in all organs with
metastasis as compared to the control or pesVEGFR-2
groups.
Blood and lymphatic microvessels in treated mammary
tumors
As shown in Figure 4A-L, the numbers of blood and
lymphatic microvessels were determined by a double
immunohistochemical staining with the blood vessel
endothelial cell marker CD34 and lymphatic vessel
endothelial marker Lyve-1. Numbers of blood
microvessels with CD34+/Lyve-1- and lymphatic micro-
vessels with CD34-/Lyve-1+ were counted on the merged
images (Figure 4C, F, I, L). The results of the analysis
showed that the number of blood microvessels was sig-
nificantly lower in the pEndo group, and the number of
lymphatic microvessels was significantly decreased in
the pesVEGFR-2 and pEndo groups, as compared to the
corresponding pVec group (Figure 3C).
Dilated lymphatic vessels with cancer cell invasion
The lymphatic microvessels in the mammary tumors
were also stained for another lymphatic endothelial mar-
ker podoplanin, as demonstrated in Figure 5A-C. Fre-
quently, tumor cells within the lumina of dilated
lymphatic vessels in the tumors were observed in both
control (Figure 5A) and treated animals (Figure 5B, C).
As shown in Figure 3D, the number of lymphatic vessels
having intralumenal cancer cells was significantly lower
in the pesVEGFR-2 and pEndo groups as compared to
the pVec group, supporting the suppression of lymph
node metastasis in these groups.
Apoptosis and cell proliferation in mammary tumor cells
Results of quantitative analysis for apoptosis in lesions,
as assessed by the TUNEL assay, are shown in Figure
5D-G; the number of TUNEL-positive cells was signifi-
cantly increased in tumors from the pEndo group (Fig-
ure 3E, Figure 5F, G) as compared to levels seen in
tumors from control mice of the pVec group (Figure
5D). No apparent differences of apoptosis levels in
tumors were observed between the pVec (Figure 5D)
and pesVEGFR-2 (Figure 5E) groups. Cell proliferation,
assessed by BrdU immunohistochemistry (Figure 5H-J),
was significantly reduced in mammary tumor cells trea-
ted with pesVEGFR-2 or pEndo than in those observed
in corresponding control tumors (Figure 3F).
Discussion
In the present study, gene therapy with vectors expres-
sing esVEGFR-2 significantly suppressed the multiplicity
of lymph node metastasis and lung metastatic nodules
in an immunocompetent metastatic mammary cancer
model, whereas pEndo (as a positive control) strongly
inhibited overall metastasis. Survival rates tended to be
prolonged in the pesVEGFR-2 and pEndo groups,
although this tendency was not statistically significant.
Tumor volume was significantly reduced in the pes-
VEGFR-2 and pEndo groups, and this reduction was
associated with decreased cell proliferation as assessed
by BrdU labeling indices. In addition, the antitumor
effects in the pEndo group were significantly stronger
than the antitumor effects in the pesVEGFR-2 group.
The inhibition of metastasis in these groups may simply
be a reflection of the suppressed tumor growth and cell
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Figure 3 Quantitative analyses of metastasis, vascular density, apoptosis, cell proliferation in mammary carcinomas. A. Multiplicity of
lymph node metastasis was significantly decreased in the pesVEGFR-2 and pEndo groups (**P < 0.01 as compared to the pVec group; †P < 0.01
as compared to the pesVEGFR-2 group). B. Multiplicity of lung metastatic foci > 250 μm was significantly reduced in the pesVEGFR-2 and pEndo
groups (**P < 0.01 as compared to the pVec group; †P < 0.01 as compared to the pesVEGFR-2 group). C. Quantitation of blood and lymphatic
microvessels were conducted using CD34 and Lyve-1 immunohistochemistry. The number of CD34+/Lyve-1- blood vessels was significantly
decreased in the pEndo group, but not in the pesVEGFR-2 group, as compared to the pVec group. The number of CD34-/Lyve-1+ lymphatic
microvessels was significantly decreased in the pesVEGFR-2 and pEndo groups. D. The mammary tumors were immunohistochemically stained
for another lymphatic endothelial marker podoplanin. The number of dilated lymphatic microvessels containing intraluminal tumor cells was
significantly lower in pesVEGFR-2 and pEndo groups than those observed in the control pVec group. E. Apoptotic cell death, assessed by TUNEL
assay, was significantly increased in the pEndo group. F. Cell proliferation, inferred by BrdU labeling indices, was significantly decreased in the
pesVEGFR-2 and pEndo groups. *P < 0.05 and **P < 0.01 as compared to the values of the pVec group. Data presented are means ± SD values.
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proliferation. However, this therapeutic benefit is appar-
ent because conventional therapies are often insufficient
to eradicate metastatic breast cancer. When the dia-
meter of malignant breast tumors reaches 4 cm or lar-
ger, the chance of tumor recurrence and/or metastasis
increases dramatically [24]. The prolonged survival,
reduced tumor volume, and suppression of metastasis
after pesVEGFR-2 therapy suggests that esVEGFR-2
may potentially represent a novel therapy for cancer
treatment.
Tumor cell dissemination is mediated by a number of
mechanisms, including direct invasion into local tissue,
lymphatic spread, and hematogenous spread. The most
common pathway of initial dissemination is via the
afferent ducts of the lymphatics [25]. The lymphatic
capillaries present in tissues and tumors provide
entrance into the lymphatic system, allowing cancer cell
migration to the lymph nodes. VEGF-C expression cor-
relates with lymph node metastasis in a variety of
human cancers, including breast neoplasms [8,26]. In
many animal models of cancer, VEGF-C enhances
tumor lymphangiogenesis, the metastatic spread of
tumor cells to lymph nodes and, in some cases, distant
organ metastasis [27]. Downregulation of VEGF-C with
siRNA reduces lymph node metastasis in murine mam-
mary cancer models [20,28]. In addition, VEGFR-3, the
VEGF-C receptor, is predominantly expressed on lym-
phatic endothelial cells [29], and VEGF-C-dependent
activation of VEGFR-3 stimulates the growth of lympha-
tic endothelial cells and lymphatics [30]. Blockade of
VEGFR-3 signaling by sVEGFR-3 or blocking antibody
inhibits lymph node metastasis in experimental animal
cancer models and is associated with a reduction in
lymphangiogenesis but not angiogenesis of tumors [2-4].
In contrast, Laakkonen et al. reported that VEGFR-3
blocking antibody therapy significantly suppresses both
angiogenesis and lymphangiogenesis [31]. In addition,
Burton et al. reported that sVEGFR-3 significantly
inhibits lymphangiogenesis and slightly inhibits tumor
blood vasculature. They speculated that the inhibition of
tumor blood vasculature could likely be responsible for
the delay in tumor growth in vivo [5].
We recently demonstrated that naturally occurring
esVEGFR-2 is a VEGF-C antagonist that selectively inhi-
bits lymphangiogenesis and is associated with normal
alymphatic cornea [7]. In fact, the present study shows
that the multiplicity of lymph node metastasis and lung
metastatic nodules was significantly reduced in the pes-
VEGFR-2 group and associated with a decreased num-
ber of lymphatic vessels but not blood vessels in
mammary carcinomas. However, as shown in Table 1,
pesVEGFR-2 did not decrease the number of unilateral
or bilateral metastasis in the lungs, ovaries, kidneys and
adrenals, which are types of hematogenous metastasis.
Thus, treatment with pesVEGFR-2 that primarily inhi-
bits lymphangiogenesis may be ineffective in this experi-
mental setting. But, since pesVEGFR-2 significantly
decreased the number of metastatic nodules in the
lungs, some possibilities are raised. An initial pathway of
lung metastasis may also be through the lymphatic path-
way (thoracic duct); cancer cells then influx into the left
subclavian vein, pass through the right ventricle of the
heart and pulmonary artery, and then settle and grow in
the lung tissue. In addition, cancer cells metastasize to
lymph nodes and invade into blood microvessels within
the lymph node and then hematogenously spread to the
lungs. If so, the number of cancer cells that metastasize
to the lungs may be decreased. Alternatively, the
secreted esVEGFR-2 in blood may inhibit the survival of
cancer cells circulating in the blood, or it may inhibit
the settlement of cancer cells in the lungs. Further
investigation is necessary to explore these possibilities.
In addition, we observed a significant decrease in the
number of lymphatic vessels with tumor cells in their
lumina in the pesVEGFR-2 and pEndo groups as com-
pared to the pVec control group. This finding indicates
Table 1 Multiplicity of any category of metastasisa)
Average No. of organs with metastasis except
for lymph nodesb)
Groups Number of
mice
examined
Total no. of
organs with
metastasis
Average no. of
organs with
metastasis/mouseb)
Lungs Ovaries Kidneys Adrenals Others
pVec 9 156 16.3 ± 3.3 2.0 ± 0.0 1.9 ± 0.3 1.6 ± 0.5 1.3 ± 0.9 0.0 ± 0.0
pesVEGFR-2 10 106 9.9 ± 4.1** 1.5 ± 0.8 1.8 ± 0.6 1.1 ± 1.0 1.6 ± 0.8 0.1 ± 0.3c)
pEndo 9 6 0.7 ± 1.1**† 0.0 ± 0.0**† 0.0 ± 0.0 **† 0.0 ± 0.0**† 0.3 ± 0.7 *† 0.1 ±0.3d)
*P< 0.05; **P < 0.01 as compared with pVec values.
†P< 0.01 as compared with pesVEGFR-2 values.
a) With respect to bilateral organs, one in unilateral metastasis and two in bilateral metastasis were counted.
b) Values are mean ± SD.
c) Metastasis to uterus.
d) Metastasis to subcutis.
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an inhibitory effect on migration into tumor lymphatic
vessels that supports a significant reduction in lymph node
metastasis in these groups. In addition, the number of
CD8+ T cells and dendritic cells is significantly increased
in inoculated murine mammary tumor cells stably trans-
fected with VEGF-C siRNA, suggesting that VEGF-C
modulates the immune response [28]. Therefore, the
immune response may participate in the antimetastatic
potential of pesVEGFR-2 in the immunocompetent mam-
mary cancer model in the present experiment.
Previous studies have found that the systemic adminis-
tration of the anti-VEGFR-3 blocking antibody inhibits
lymph node metastasis and reduces lymphatic vessel
density in orthotopic lung [2] or gastric tumors [3] in
Figure 4 Immunofluorescence for blood and lymphatic vessels in mammary carcinomas. Double immunohistochemical staining with
CD34 for blood microvessels (red) and Lyve-1 for lymphatic (green) microvessels and their merged images in mammary tumors. As can be seen
in their merged image (C), some microvessels showed both expressions of CD34 (A) and Lyve-1 (B). Such microvessels having CD34+/Lyve-1+
characteristics were excluded from quantitation. The number of lymphatic microvessels was lower in the pesVEGFR-2 (G-I, merge in I) and
pEndo (J-L, merge in L) groups than in the pVec group (D-F, merge in F). A-L, scale bar = 50 μm.
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Figure 5 Dilated lymphatic vessels with cancer cell invasion, apoptosis, and cell proliferation in mammary carcinomas. Podoplanin-
positive lymphatic microvessels of a tumor in a control mouse were often dilated and filled with tumor cells (A). The pesVEGFR-2 (B) and pEndo
(C) groups showed a reduction in the numbers of dilated lymphatic microvessels containing intralumenal tumor cells (A-C, scale bar = 50 μm).
Whereas some TUNEL-positive cells are seen in the tumor of a control mouse (D) and a mouse treated with pesVEGFR-2 (E), many more TUNEL-
positive cells are observed in the tumor of a mouse treated with pEndo (F) (D-F, scale bar = 50 μm). Higher magnification in F showed many
TUNEL-positive cells are observed in along with brownish necrotic vessels (G, arrows) (scale bar = 25 μm). Apoptosis of the tumor cells may be
due to injury of the blood vessels (blockage of oxygen supply and nutrition to tumor cells). The number of BrdU-labeled cells tended to be
lower in the pesVEGFR-2 (I) and pEndo (J) groups than in the pVec group (H) (H-J, scale bar = 50 μm). A-C, podoplanin immunohistochemistry;
D-G, TUNEL stain; H-J, BrdU immunohistochemistry.
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nude mice. However, there were no changes in angio-
genesis or tumor weight. The results of the present
study raise the question of why esVEGFR-2 suppresses
tumor growth without suppressing tumor angiogenesis.
VEGF-C induces tumor growth in orthotopic prostate
tumors [32] or gastric carcinomas [33] in nude mice.
Indeed, in the present study, esVEGFR-2 decreased cell
proliferation as determined by BrdU-labeling indices.
Since esVEGFR-2 is an antagonist of VEGF-C, it is possi-
ble that pesVEGFR-2 could inhibit tumor growth as well,
as indicated by the present study. On a related note,
sVEGFR-3 can not only bind VEGFR-3 but also acts as a
trap for VEGF-C, which blocks VEGFR-3 signaling [2,5].
Endostatin is a 20-kDa C-terminal fragment of collagen
XVIII that inhibits endothelial cell proliferation and
tumor angiogenesis by several mechanisms. These
mechanisms include: blocking the binding of VEGF121
and VEGF165 to the KDR/Flk-1 receptor, which mediates
endothelial cell motility and proliferation; blocking phos-
phorylation of the tyrosine receptor; and blocking activa-
tion of the intracellular signaling kinases ERK, p38
MAPK, and p125 FAK [34,35]. Gene therapy with endo-
statin causes significant tumor growth arrest in various
cancers in laboratory animals [36,37]. We previously
showed that gene therapy with endostatin suppresses
tumor growth and metastasis (lymph nodes and lungs)
and is associated with the inhibition of blood vessels and
lymphatic vessels in the mouse mammary cancer model
[15], which is consistent with the results of the present
study. Brideau et al. reported that J4 transgenic mice
overexpressing endostatin (driven by the keratin K14
promoter) in epidermal basal cells exhibited inhibited
angiogenesis and lymphangiogenesis in skin tumors
induced by a carcinogen followed by a tumor promoter
agent [16]. The skin tumors in the J4 transgenic mice
were less aggressive than tumors in wild-type mice [16].
Thus, endostatin inhibits both blood vessels and lympha-
tic vessels. Endostatin is a naturally occurring molecule
like pesVEGFR-2, not a recombinant protein; hence, we
selected endostatin as a positive control. In the present
study, pEndo strongly suppressed overall metastasis (lym-
phatic and hematogenous metastasis) and was associated
with decreased angiogenesis and lymphangiogenesis in
tumors. A possible reason why metastasis in the pes-
VEGFR-2 group was not strong as compared to the
pEndo group is that pesVEGFR-2 inhibited tumor lym-
phangiogenesis but not angiogenesis.
Conclusions
We have demonstrated that gene therapy with alternative
splicing variant esVEGFR-2 (a new specific inhibitor of
lymphangiogenesis [7]) significantly suppresses tumor
growth and lymph node metastasis in a mouse mammary
cancer model. In most types of cancer, the first site of
metastasis is lymph nodes, and the extent of lymph node
involvement is a major criterion for evaluating patient
prognosis. Therefore, we believe the antimetastatic activ-
ity of esVEGFR-2 may have great clinical significance for
the treatment of metastatic human breast cancer.
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